The DOI matches its Crossref record.
Modulation of Survival Motor Neuron Pre-mRNA Splicing by Inhibition of Alternative 3′ Splice Site Pairing
Open accessAbstract
Spinal muscular atrophy is caused by the loss of functional survival motor neuron (SMN1) alleles. A translationally silent nucleotide transition in the duplicated copy of the gene (SMN2) leads to exon 7 skipping and expression of a nonfunctional gene product. It has been suggested that differential SMN2 splicing is caused by the disruption of an exonic splicing enhancer. Here we show that the single nucleotide difference reduces the intrinsic strength of the 3' splice site of exon 7 2-fold, whereas the strength of the 5' splice site of the exon 7 is not affected. Thus, a decrease in splice site strength is magnified in the context of competing exons. These data suggest that lower levels of exon 7 definition not only reduce intron 6 removal but, more importantly, increase the efficiency of the competing exon 7 skipping pathway. Antisense oligonucleotides were tested to modulate exon 7 inclusion, which contains the authentic translation stop codon. Oligonucleotides directed toward the 3' splice site of exon 8 were shown to alter SMN2 splicing in favor of exon 7 inclusion. These results suggest that antisense oligonucleotides could be used as a therapeutic strategy to counteract the progression of SMA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Listening to silence and understanding nonsense: exonic mutations that affect splicing
Cartegni, L., Chew, S. L., & Krainer, A. R. (2002) · Nature Reviews Genetics · doi:10.1038/nrg775 · Cited by 2,209
Cartegni, L., & Krainer, A. R. (2002) · Nature Genetics · doi:10.1038/ng854 · Cited by 730
Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 664
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 632
Kolb, S. J., & Kissel, J. T. (2015) · Neurologic Clinics · doi:10.1016/j.ncl.2015.07.004 · Cited by 603
D'Amico, A., Mercuri, E., Tiziano, F. D., & Bertini, E. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-71 · Cited by 577
Splice-switching antisense oligonucleotides as therapeutic drugs
Havens, M. A., & Hastings, M. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw533 · Cited by 538
Rescue of Dystrophic Muscle Through U7 snRNA-Mediated Exon Skipping
Goyenvalle, A., Vulin, A., Fougerousse, F., Leturcq, F., Kaplan, J.-C., Garcia, L., & Danos, O. (2004) · Science · doi:10.1126/science.1104297 · Cited by 506
Singh, N. K., Singh, N. N., Androphy, E. J., & Singh, R. N. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1333-1346.2006 · Cited by 454
Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon
Hua, Y., Vickers, T. A., Baker, B. F., Bennett, C. F., & Krainer, A. R. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050073 · Cited by 340
Spinal Muscular Atrophy: A Timely Review
Kolb, S. J. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.74 · Cited by 333
Determinants of Exon 7 Splicing in the Spinal Muscular Atrophy Genes, SMN1 and SMN2
Cartegni, L., Hastings, M. L., Calarco, J. A., de Stanchina, E., & Krainer, A. R. (2006) · The American Journal of Human Genetics · doi:10.1086/498853 · Cited by 306
Correction of disease-associated exon skipping by synthetic exon-specific activators
Cartegni, L., & Krainer, A. R. (2003) · Nature Structural Biology · doi:10.1038/nsb887 · Cited by 301
Treating Disease at the RNA Level with Oligonucleotides
Levin, A. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1705346 · Cited by 287
Antisense oligonucleotides in therapy for neurodegenerative disorders
Evers, M. M., Toonen, L. J. A., & van Roon-Mom, W. M. C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.03.008 · Cited by 286
Rigo, F., Chun, S. J., Norris, D. A., Hung, G., Lee, S., Matson, J., Fey, R. A., Gaus, H., Hua, Y., Grundy, J. S., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.212407 · Cited by 283
“…to replace SMN protein (Foust et al., 2010; Passini et al., 2010); antisense oligonucleotide (ASO)– based approaches to correct SMN2 splicing (Lim and Hertel, 2001; Miyajima et al., 2002; Cartegni and Krainer, 2003; Skordis et al., 2003; Singh et al., 2006; Hua et al., 2007, 2008, 2011;…”
BackgroundSkordis, L. A., Dunckley, M. G., Yue, B., Eperon, I. C., & Muntoni, F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0633863100 · Cited by 274
Spinal muscular atrophy: mechanisms and therapeutic strategies
Lorson, C. L., Rindt, H., & Shababi, M. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq147 · Cited by 209
Antisense-Mediated RNA Targeting: Versatile and Expedient Genetic Manipulation in the Brain
Zalachoras, I., Evers, M. M., van Roon-Mom, W. M. C., Aartsma-Rus, A. M., & Meijer, O. C. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00010 · Cited by 24
Metadata
- Authors
- Lim, S. R., & Hertel, K. J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2001-11
- Volume
- 276
- Issue
- 48
- Pages
- 45476-45483
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2105010877
- Cited by
- 159
- References
- 0
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.